Biogen Inc (BIIB) Actualités

New Higher Dose Nusinersen Efficacy and Safety Data Presented at World Muscle Society Congress, Highlight Potential to Maximize Benefit of Nusinersen in SMA

Findings from Part B and Part C of the DEVOTE study support the clinical benefits of a higher dose regimen of...

Form 3 - Initial statement of beneficial ownership of securities

UCB and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus and are Initiating Second Phase 3 Study in 2024

Phase 3 PHOENYCS GO study met the primary endpoint demonstrating clinical improvement in moderate-to-severe...

Form 8-K - Current report

Biogen Board Appoints Two New Independent Directors

CAMBRIDGE, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- The Biogen Inc. (Nasdaq: BIIB) Board of Directors (the...

Form 4 - Statement of changes in beneficial ownership of securities

Biogen Announces Positive Topline Results from Study of Higher Dose Regimen of Nusinersen, Showing Significant Benefit in Treatment of SMA

Positive study demonstrates the potential for investigational higher dose nusinersen regimen to advance the...

Form 144 - Report of proposed sale of securities

Leqembi® (lecanemab) Authorized for Early Alzheimer's Disease in Great Britain

Leqembi® (lecanemab) Authorized for Early Alzheimer's Disease in Great Britain PR Newswire TOKYO and CAMBRIDGE, Mass., Aug. 22, 2024 FOR GLOBAL...

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Alcyone Therapeutics Announces Continued Enrollment Approval from FDA of the PIERRE Pivotal IDE Clinical Study of the ThecaFlex DRx™ System for Administration of nusinersen

Alcyone Therapeutics Announces Continued Enrollment Approval from FDA of the PIERRE Pivotal IDE Clinical Study of the ThecaFlex DRx™ System for...

New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI® (lecanemab-irmb) Continues to Significantly Benefit Early Alzheimer’s Disease Patients Presented at The Alzheimer’s Association International Conference (AAIC

51% of No Tau / Low Tau Patients Showed Improved Cognition and Function Over Three Years; Only Lecanemab Has...